Dayspring Pharma today announced top-line data from its Phase II clinical trial of CG2001 foam in male patients with androgenetic alopecia (AGA). The trial met its primary endpoint and demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results